Exhibit 1283 ยท GAO report
Food and Drug Administration: Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities (GAO-02-958)
user fees funded 7 percent of drug and biologic review obligations in fiscal year 1993, user fees accounted for nearly 50 percent of the total funds obligated for the drug and biologic review processes in fiscal year 2001.
GAO reports the share of FDA's drug and biologic review obligations paid from user fees: 7 percent in fiscal year 1993, nearly 50 percent in fiscal year 2001, and 51 percent expected for fiscal year 2002.
- Source
- U.S. General Accounting Office
- Date
- September 2002
- Quoted from
- GAO-02-958, printed p. 8 (section 'PDUFA Has Increased Funding and Reduced Drug Approval Time...')
- Grade
- Primary record
- Document
- https://files.gao.gov/assets/gao-02-958.pdf
- Accessed
- 2026-11-10
- Cited by
- Findings citing this exhibit